Categories AlphaGraphs, Consumer, Earnings
LULU Earnings: Highlights of Lululemon’s Q4 2023 financial results
Athletic wear company Lululemon Athletica (NASDAQ: LULU) reported an increase in revenues and profit for the fourth quarter of 2023. The company also issued guidance for the first quarter of 2024.
Fourth-quarter revenues increased 16% year-over-year to $3.2 billion. There was a 12% growth in comparable sales. Americas net revenue increased 9% and international revenue jumped 54%.
Net income jumped to $669.5 million or $5.29 per share during the three months from $119.8 million or $0.94 per share last year. Gross profit increased 25% to $1.9 billion.
For the first quarter of 2024, the company expects net revenue to be in the range of $2.175 billion to $2.200 billion, representing growth of 9-10%. Earnings, on a per-share basis, are expected to be in the range of $2.35 to $2.40 for the quarter. This assumes a tax rate of 29.0% to 29.5%.
Lululemon’s CEO Calvin McDonald said, “During the fourth quarter, we saw continued momentum across our channels, geographies, and merchandise categories, driven by our teams around the world. As we step into 2024, we are focused on the significant opportunities ahead for Lululemon as we navigate the dynamic retail environment and deliver for guests through innovative new products and brand activations.”
Listen to the conference calls as they happen. Don't miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report
Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,
J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights
The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was
Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials
Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs